Safety of hydroxychloroquine for treatment or prevention of SARS-CoV-2 infection: A rapid systematic review and meta-analysis of randomized clinical trials

被引：8
作者：
Maraolo, Alberto Enrico [1 ]
Grossi, Adriano [2 ]
机构：
[1] Cotugno Hosp, Div Infect Dis 1, Naples, Italy
[2] Univ Cattolica Sacro Cuore, Univ Dept Life Sci & Publ Hlth, Sect Hyg, Rome, Italy
来源：
IMMUNITY INFLAMMATION AND DISEASE | 2021年 / 9卷 / 01期
关键词：
COVID-19; hydroxychloroquine; meta-analysis; randomized controlled trials; safety; SARS-CoV-2;
D O I：
10.1002/iid3.374
中图分类号：
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号：
100102 ;
摘要：
Introduction: Hydroxycloroquine (HCQ) has been extensively studied for treatment and prevention of coronavirus diseases 2019 (COVID-19) from the start of the pandemic. Conflicting evidence about its usefulness has begun to accrue. Methods: In the face of controversial results about clinical efficacy of HCQ, we performed a rapid systematic review to assess its safety in the framework of COVID-19 randomized clinical trials. Results: Five studies investigating 2291 subjects were included. The use of HCQ was associated with higher risk of adverse event compared with placebo or standard of care: odds ratio 4.57, 95% confidence interval 2.14-9.45. Conclusion: Safety profile of HCQ appears to be unsatisfactory when used to treat or prevent COVID-19, especially in the light of unproved clinical benefit.
引用
收藏
页码：31 / 36
页数：6
相关论文
共 15 条
  • [1] Aronson JK, More about chloroquine and hydroxychloroquine
  • [2] A Randomized Trial of Hydroxychloroquine as Postexposure Prophylaxis for Covid-19
    Boulware, David R.
    Pullen, Matthew F.
    Bangdiwala, Ananta S.
    Pastick, Katelyn A.
    Lofgren, Sarah M.
    Okafor, Elizabeth C.
    Skipper, Caleb P.
    Nascene, Alanna A.
    Nicol, Melanie R.
    Abassi, Mahsa
    Engen, Nicole W.
    Cheng, Matthew P.
    LaBar, Derek
    Lother, Sylvain A.
    MacKenzie, Lauren J.
    Drobot, Glen
    Marten, Nicole
    Zarychanski, Ryan
    Kelly, Lauren E.
    Schwartz, Ilan S.
    McDonald, Emily G.
    Rajasingham, Radha
    Lee, Todd C.
    Hullsiek, Kathy H.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2020, 383 (06) : 517 - 525
  • [3] Hydroxychloroquine with or without Azithromycin in Mild-to-Moderate Covid-19
    Cavalcanti, A. B.
    Zampieri, F. G.
    Rosa, R. G.
    Azevedo, L. C. P.
    Veiga, V. C.
    Avezum, A.
    Damiani, L. P.
    Marcadenti, A.
    Kawano-Dourado, L.
    Lisboa, T.
    Junqueira, D. L. M.
    de Barros e Silva, P. G. M.
    Tramujas, L.
    Abreu-Silva, E. O.
    Laranjeira, L. N.
    Soares, A. T.
    Echenique, L. S.
    Pereira, A. J.
    Freitas, F. G. R.
    Gebara, O. C. E.
    Dantas, V. C. S.
    Furtado, R. H. M.
    Milan, E. P.
    Golin, N. A.
    Cardoso, F. F.
    Maia, I. S.
    Hoffmann Filho, C. R.
    Kormann, A. P. M.
    Amazonas, R. B.
    Bocchi de Oliveira, M. F.
    Serpa-Neto, A.
    Falavigna, M.
    Lopes, R. D.
    Machado, F. R.
    Berwanger, O.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2020, 383 (21) : 2041 - 2052
  • [4] Safety of hydroxychloroquine in COVID-19 and other diseases: a systematic review and meta-analysis of 53 randomized trials
    Chen, Can
    Pan, Kunming
    Wu, Bingjie
    Li, Xiaoye
    Chen, Zhangzhang
    Xu, Qing
    Li, Xiaoyu
    Lv, Qianzhou
    [J]. EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2021, 77 (01) : 13 - 24
  • [5] Effect of hydroxychloroquine with or without azithromycin on the mortality of coronavirus disease 2019 (COVID-19) patients: a systematic review and meta-analysis
    Fiolet, Thibault
    Guihur, Anthony
    Rebeaud, Mathieu Edouard
    Mulot, Matthieu
    Peiffer-Smadja, Nathan
    Mahamat-Saleh, Yahya
    [J]. CLINICAL MICROBIOLOGY AND INFECTION, 2021, 27 (01) : 19 - 27
  • [6] Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial
    Gautret, Philippe
    Lagier, Jean-Christophe
    Parola, Philippe
    Van Thuan Hoang
    Meddeb, Line
    Mailhe, Morgane
    Doudier, Barbara
    Courjon, Johan
    Giordanengo, Valerie
    Vieira, Vera Esteves
    Dupont, Herve Tissot
    Honore, Stephane
    Colson, Philippe
    Chabriere, Eric
    La Scola, Bernard
    Rolain, Jean-Marc
    Brouqui, Philippe
    Raoult, Didier
    [J]. INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 2020, 56 (01)
  • [7] Safety considerations for chloroquine and hydroxychloroquine in the treatment of COVID-19
    Gevers, S.
    Kwa, M. S. G.
    Wijnans, E.
    van Nieuwkoop, C.
    [J]. CLINICAL MICROBIOLOGY AND INFECTION, 2020, 26 (09) : 1276 - 1277
  • [8] Plea for routinely presenting prediction intervals in meta-analysis
    IntHout, Joanna
    Ioannidis, John P. A.
    Rovers, Maroeska M.
    Goeman, Jelle J.
    [J]. BMJ OPEN, 2016, 6 (07):
  • [9] Khalafallah A, 2010, MEDITERR J HEMATOL I, V2, DOI [10.1136/bmj.l4898, 10.4084/MJHID.2010.005]
  • [10] Hydroxychloroquine for Early Treatment of Adults With Mild Coronavirus Disease 2019: A Randomized, Controlled Trial
    Mitja, Oriol
    Corbacho-Monne, Marc
    Ubals, Maria
    Tebe, Cristian
    Penafiel, Judith
    Tobias, Aurelio
    Ballana, Ester
    Alemany, Andrea
    Riera-Marti, Nuria
    Perez, Carla A.
    Suner, Clara
    Laporte, Pep
    Admella, Pol
    Mitja, Jordi
    Clua, Mireia
    Bertran, Laia
    Sarquella, Maria
    Gavilan, Sergi
    Ara, Jordi
    Argimon, Josep M.
    Casabona, Jordi
    Cuatrecasas, Gabriel
    Canadas, Paz
    Elizalde-Torrent, Aleix
    Fabregat, Robert
    Farre, Magi
    Forcada, Anna
    Flores-Mateo, Gemma
    Muntada, Esteve
    Nadal, Nuria
    Narejos, Silvia
    Nieto, Aroa
    Prat, Nuria
    Puig, Jordi
    Quinones, Carles
    Reyes-Urena, Juliana
    Ramirez-Viaplana, Ferran
    Ruiz, Lidia
    Riveira-Munoz, Eva
    Sierra, Alba
    Velasco, Cesar
    Maria Vivanco-Hidalgo, Rosa
    Sentis, Alexis
    G-Beiras, Camila
    Clotet, Bonaventura
    Vall-Mayans, Marti
    [J]. CLINICAL INFECTIOUS DISEASES, 2021, 73 (11) : E4073 - E4081
12